CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

Planning Enters Next Hhase as ABMS Announces Open Comment Period

Efforts by the American College of Cardiology, the American Heart Association, the Heart Failure Society of America, the Heart Rhythm Society and The Society for Cardiovascular Angiography & Interventions to create a new, independent Board of Cardiovascular Medicine under the American Board of Medical Specialties (ABMS) are closer to becoming a reality with the creation of a formal Board of Directors and the announcement by the ABMS Advisory Board on Specialty Board Development of an open comment period.

The 90-day open comment period announced by ABMS on April 24 is a critical part of the application review process and a vital cornerstone for engagement in the decision-making process. Running through July 24, ABMS is seeking to gauge support for the new Board, including feedback on its impact to clinicians and patients.

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

A diverse range of stakeholders, including cardiologists, other health care professionals, cardiovascular patients, cardiovascular organizations, and the public are invited to share their perspectives on the new Board, including whether it meets the ABMS requirements for both initial certification and continuing competency. Comments can be submitted via the ABMS website.

In addition to the comment period, the first 10 directors of the prospective Board have been selected, with an additional five directors soon to be named. As leaders in their respective fields, the Board of Directors will be instrumental in ushering the new Board through the application process and overseeing pre-launch projects in anticipation of Board approval.

The initial Directors include:

  • Mark H. Drazner, MD (Treasurer)
  • Peter L. Duffy, MD
  • David P. Faxon, MD
  • Edward T. A. Fry, MD
  • Judith S. Hochman, MD
  • Jodie L. Hurwitz, MD (Secretary)
  • Michelle Maya Kittleson, MD
  • Daniel M. Kolansky, MD
  • Jeffrey T. Kuvin, MD (President)
  • Gregory F. Michaud, MD

“Cardiologists have a responsibility to maintain clinical competency to ensure patients receive the best possible care. To facilitate career-long learning, a new model of certification tailored to the unique needs of cardiology is needed,” the Directors said in a joint statement. “An independent Board focused solely on cardiovascular medicine as a distinct medical specialty will ultimately benefit cardiologists and patients alike.”

The Directors’ initial work will establish the framework needed to pave the way for a successful launch of the proposed Board of Cardiovascular Medicine, which includes crafting clear bylaws that outline the Board’s structure and decision-making processes, establishing vital committees to manage specific Board processes and subspecialties, developing a sound budget, managing financial processes, and defining a tailored continuous competency certification process.

About the Proposed Board of Cardiovascular Medicine

For over 80 years, cardiovascular medicine has been incorporated under the American Board of Internal Medicine (ABIM). However, given decades of advancements in the field, cardiologists across the country have come together to move towards a new Board that recognizes cardiovascular medicine as a medical specialty distinct from internal medicine. The proposed independent Board of Cardiovascular Medicine, governed by cardiologists for cardiologists, would facilitate a deep understanding of competencies to ensure high-value cardiovascular patient care. The underpinnings of true lifelong learning and practical skills development proposed by the new Board will support clinicians in achieving and maintaining clinical competency. For more information, visit: https://CVBoard.org.

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.